RANI Collapses 24%: What Just Triggered This Biotech Bloodbath?

Summary
• Rani Therapeutics (RANI) tumbles 24.06% intraday to a low of $0.82, its lowest level since mid-2024.
• Bollinger Bands and RSI signal extreme bearish momentum, with RSI plummeting to 34.29, entering oversold territory.
• Options volatility surges, with IV ratios on key contracts spiking above 140% and leverage ratios spiking into the 160% range.

Rani Therapeutics is experiencing a catastrophic intraday selloff as the stock crashes below critical support levels. With no immediate news to explain the drop, traders are scrambling to interpret the technicals and options signals. A sharp bearish reversal pattern is forming, with high volatility and leveraged options suggesting a possible continuation of the downward spiral.

Bearish K-Line Confirms Short-Term Downtrend
The sharp intraday drop in RANI is being driven by a clear bearish K-line pattern, signaling a short-term reversal and a continuation of selling pressure. The stock is now trading far below both the 30-day and 200-day moving averages, which sit at $1.28 and $1.06 respectively. The MACD has crossed below the signal line, reinforcing bearish momentum, while the RSI has entered oversold territory, suggesting potential for further downside. The move reflects deepening bearish conviction among traders, as the stock slides into a new trading range below $1.00 and into the $0.80s.

Biotech Sector in Retreat, Biotech Giants Mirror Volatility
The broader biotech sector is showing signs of weakness, with Amazon (AMZN)—a sector leader in e-commerce and digital health—dropping 3.6% intraday. While AMZN's decline is not directly tied to RANI's sharp selloff, the correlated volatility suggests a broader shift in risk appetite and sector sentiment. Investors are likely reassessing exposure to high-beta and speculative biotech plays, which have historically shown strong co-movements during periods of market stress.

Options Volatility Soars: Leveraged Bets and Time Decay Strategies in Focus
• RSI: 34.29 (oversold)
• MACD: -0.05918 (bearish), Signal Line: -0.03525 (bearish), Histogram: -0.02394 (divergence)
• Bollinger Bands: $1.49 (Upper), $1.266 (Middle), $1.046 (Lower)
• 200-day MA: $1.064 (near support)
• 30-day MA: $1.278 (resistance)

With RANI falling rapidly and breaking key support levels, the technical picture has turned aggressively bearish. The stock is now trading near the lower Bollinger Band and the 200-day MA, which could act as a potential floor in the short term. Given the high volatility and sharp move down, leveraged short-term options are attracting attention from aggressive traders.

RANI20261016C1 is one of the standout calls for bearish exposure. This October 16, 2026, call option has a strike of $1.00, an implied volatility of 149.39%, and a delta of 0.652. Despite being a call, its high leverage ratio of 2.70% and high gamma (0.408) make it a strong bet for a continuation of the bearish trend due to its sensitivity to price changes and time decay (theta: -0.000869). The high turnover (600) also ensures liquidity. A 5% downside from $0.8201 would result in a payoff of $0.18 if the stock closes at $0.78, making this contract a high-risk/high-reward call option.

RANI20261016P1 is the top put option to consider, with a strike of $1.00, a delta of -0.508, and implied volatility at 79.02%. The put has a moderate leverage ratio of 2.70%, and while the theta is -0.000314, the gamma of 0.833 suggests strong sensitivity to price movements. This contract is well-positioned for a prolonged bearish move, with a projected payoff of $0.22 under a 5% downside scenario. The high IV and moderate delta make it a balanced bet for conservative short-side traders.

Aggressive bearish traders should consider RANI20261016P1 into a breakdown below $0.80, while RANI20261016C1 offers high leverage for those expecting further acceleration downward.

Backtest Rani Therapeutics Stock Performance
The backtest of RANI's performance after a -24% intraday plunge from 2022 to the present reveals mixed results. While the ETF has experienced a maximum return of 0.82% during the backtest period, the overall trend has been negative, with a 3-day return of -0.22%, a 10-day return of -0.69%, and a 30-day return of -3.04%. The win rates also indicate a higher probability of positive returns in the short term, with a 3-day win rate of 48.70%, a 10-day win rate of 43.52%, and a 30-day win rate of 38.15%.

Bear Market Signal Ignites: RANI at Crossroads
RANI is in the midst of a sharp bearish reversal that has wiped out nearly a quarter of its intraday value. The stock is now trading near the lower Bollinger Band and has broken below the 200-day moving average, a critical technical threshold. Options volatility is spiking, and leveraged contracts are seeing strong buying interest, indicating that traders are preparing for more downside. Amazon (AMZN) is also in retreat, signaling broader sector weakness. The most critical levels to watch are the $0.80 psychological level and the $0.458–$0.5075 support band near the 200-day low. If RANI closes below $0.80, the bearish momentum is likely to accelerate, making the $0.78 level the next key trigger point for aggressive short-side plays.